[go: up one dir, main page]

WO2003028670A1 - Ciment de reaction polyacide - Google Patents

Ciment de reaction polyacide Download PDF

Info

Publication number
WO2003028670A1
WO2003028670A1 PCT/GB2002/004359 GB0204359W WO03028670A1 WO 2003028670 A1 WO2003028670 A1 WO 2003028670A1 GB 0204359 W GB0204359 W GB 0204359W WO 03028670 A1 WO03028670 A1 WO 03028670A1
Authority
WO
WIPO (PCT)
Prior art keywords
oxide powder
oxide
cement
polyacid
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2002/004359
Other languages
English (en)
Inventor
Paul Vincent Hatton
Ian Michael Reaney
Kathryn Hurrell-Gillingham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sheffield
Original Assignee
University of Sheffield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sheffield filed Critical University of Sheffield
Publication of WO2003028670A1 publication Critical patent/WO2003028670A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/07—Stiffening bandages
    • A61L15/12—Stiffening bandages containing macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/30—Compositions for temporarily or permanently fixing teeth or palates, e.g. primers for dental adhesives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/50—Preparations specially adapted for dental root treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/884—Preparations for artificial teeth, for filling teeth or for capping teeth comprising natural or synthetic resins
    • A61K6/887—Compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/0047—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L24/0073—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix
    • A61L24/0089—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material with a macromolecular matrix containing inorganic fillers not covered by groups A61L24/0078 or A61L24/0084
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/12—Ionomer cements, e.g. glass-ionomer cements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/446—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with other specific inorganic fillers other than those covered by A61L27/443 or A61L27/46
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C8/00—Enamels; Glazes; Fusion seal compositions being frit compositions having non-frit additions
    • C03C8/02—Frit compositions, i.e. in a powdered or comminuted form
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C8/00—Enamels; Glazes; Fusion seal compositions being frit compositions having non-frit additions
    • C03C8/02—Frit compositions, i.e. in a powdered or comminuted form
    • C03C8/06—Frit compositions, i.e. in a powdered or comminuted form containing halogen
    • C—CHEMISTRY; METALLURGY
    • C03—GLASS; MINERAL OR SLAG WOOL
    • C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
    • C03C8/00—Enamels; Glazes; Fusion seal compositions being frit compositions having non-frit additions
    • C03C8/02—Frit compositions, i.e. in a powdered or comminuted form
    • C03C8/08—Frit compositions, i.e. in a powdered or comminuted form containing phosphorus
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B14/00—Use of inorganic materials as fillers, e.g. pigments, for mortars, concrete or artificial stone; Treatment of inorganic materials specially adapted to enhance their filling properties in mortars, concrete or artificial stone
    • C04B14/02—Granular materials, e.g. microballoons
    • C04B14/04—Silica-rich materials; Silicates
    • C04B14/22—Glass ; Devitrified glass
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B22/00—Use of inorganic materials as active ingredients for mortars, concrete or artificial stone, e.g. accelerators or shrinkage compensating agents
    • C04B22/06—Oxides, Hydroxides
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B28/00—Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements
    • C04B28/28—Compositions of mortars, concrete or artificial stone, containing inorganic binders or the reaction product of an inorganic and an organic binder, e.g. polycarboxylate cements containing organic polyacids, e.g. polycarboxylate cements, i.e. ionomeric systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B2111/00—Mortars, concrete or artificial stone or mixtures to prepare them, characterised by specific function, property or use
    • C04B2111/00474—Uses not provided for elsewhere in C04B2111/00
    • C04B2111/00836—Uses not provided for elsewhere in C04B2111/00 for medical or dental applications
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B2111/00—Mortars, concrete or artificial stone or mixtures to prepare them, characterised by specific function, property or use
    • C04B2111/10—Compositions or ingredients thereof characterised by the absence or the very low content of a specific material
    • C04B2111/105—Alumina-free or very low alumina-content materials

Definitions

  • the present invention relates to a polyacid reaction cement comprising an oxide powder, more particularly a polyacid reaction bone cement comprising an Fe based oxide powder, which is adapted for injection and adhesion, and a process for the preparation thereof, a polyacid cement composition and method for the preparation thereof, a two part cement pack comprising a mixed polyacid and oxide powder component and an initiator component, novel oxide powders and the use thereof as a cement in biomedical or dentistry application for the human or animal body, or for industrial application and the like, more particularly the use thereof as a bone cement for otolaryngology, orthopaedics and bone reconstruction in particular maxillofacial reconstruction, thermal tumour treatment and for release of medicaments to treat bone conditions.
  • Polyacid cements such as polymethyl methacrylic acid (PMMA) cements are known for use in orthopaedics. These are non adhesive and have further problems such as poor biocompatability, exotherm and the like. They differ significantly in composition and behaviour and are not of any appreciable use as bone cements.
  • PMMA polymethyl methacrylic acid
  • Septopal® beads are made from PMMA bone cement and loaded with antibiotics such as gentamycin. They are preformed and not suited to complex defects.
  • Dental cements have been known and used for many years comprising polyacid/base reaction cements comprising oxide powders for example as disclosed in GB 1422337 and WO 97/31877. These cements contain both carbon-carbon and metal-oxygen bonds and are employed as dental restorative materials, and are formed by the neutralisation reaction of poly acids with calcium alumino silicates or zinc oxides. The cements retain the generic properties of the polyacid cements, biocompatibility, conformability and fluoride release together with the individual advantages of the oxide powder cement.
  • cements are prepared in situ by mixing a water soluble polyacid, an oxide powder prepared by the heat treatment of precursors such as silica, alumina, calcium and aluminium fluorides and aluminium phosphate and grinding to a powder.
  • precursors such as silica, alumina, calcium and aluminium fluorides and aluminium phosphate and grinding to a powder.
  • the cements are used with initiators and the like and are suited for moulding and exposing to UV light for rapid curing.
  • Bone cements have more recently been used in many branches of surgery.
  • One specific cement, based on the dental glass-ionomer (GIC) cements is used in otolaryngology to repair the ossicular chain, and fix the electrode in cochlear implant surgery. Its use is limited because it leaches aluminium ions that inhibit bone mineralisation, and have even been linked to the death of patients undergoing skull based surgery.
  • GIC dental glass-ionomer
  • Medical ceramics comprising mixed oxides, for example as orthopaedic dental prostheses and the like containing oxides of silica, aluminium, calcium, lithium, potassium, phosphorus, iron and sulphur and the like; or as heat generating ceramics for hypothermia treatment for example of bone cancer as disclosed in EP 361797 and comprising ferro-magnetic ferrite particles dispersed in an inorganic hydroxy apatite matrix; or as prolonged release devices for human and veterinary use. These materials are however based on particulate glasses or ceramics, they are non adhesive and prone to migration.
  • an injectable adhesive bone cement which is non toxic and can be adapted for generating bone growth, bone reconstruction, controlled release of medicaments, thermal treatment of tumours and the like providing a versatile cement and which is moreover non toxic and does not inhibit local bone mineralisation.
  • a novel polyacid reaction cement comprising an iron oxide powder may be provided, which is injectable and adhesive and is useful in all of the above applications.
  • the cement has potential applications in dentistry, biomedical and general industrial application and overcomes all of the aforementioned advantages.
  • an oxide powder for a polyacid reaction cement comprising iron oxide which is adapted to be mixed with a polyacid for reaction and setting.
  • the iron oxide may be present as a single oxide or as a mixed oxide together with additional cement forming and biocompatability conferring and other active or inert oxides. It is a particular advantage of the invention that the cement is injectable and adhesive prior to setting and forms a non-brittle cement after setting.
  • the oxide powder comprises iron III oxide, preferably Fe 2 0 3 comprised in an amount of 10 to 100 mole %.
  • Other oxides present may include iron II oxide, such as FeO which may be formed by in situ reduction or may be combined with the iron III oxide, and/or other cement forming and biocompatibility conferring oxides present as a mixed oxide with the iron III oxide.
  • the oxide powder may be a fused oxide powder, as known in the art, which has been heat treated at elevated temperature to confer glass like properties.
  • Preferred additional cement forming oxides are selected from oxides of silicon and of alkaline earth in a quantity which would be, at least locally, insufficient by itself to form an acid degradable glass with iron and silicon. More preferably additional cement forming oxides are selected from Si0 2 , CaO, Sr0 2) P 2 0 5 . Preferably the phosphate content is selected to vary the setting time and/or properties.
  • the oxide powder may additionally comprise a non- oxide in the form of a fluoride. Preferably a fluoride is CaF 2 .
  • the oxide powder may additionally comprise oxides such as oxides of La, Na or K and the like.
  • the oxide of the invention retains the generic properties of GICs such as adhesion, low setting exotherm and, in optional fluoride release, has improved biocompatibility through the absence of Al and is ion-leachable in known manner.
  • the oxide powder of the invention preferably comprises substantially no Al ions. Although it is within the scope of the invention that these may be present, it is a particular advantage that these are absent whereby biocompatability and toxicity are improved.
  • the oxide powder of the invention comprises oxides and fluorides in relative amounts shown in Table 1.
  • the oxides and fluorides in Table 1 provide at least the cement forming component of the powder, the components and amounts may be selected for cement forming in known manner. Additional oxides such as oxides of Sr, La or Ba may be present enabling the product cement to be visible by x-ray, or oxides of Na or K may be present to lower the glass melting point in manufacture of the fused oxide. Additionally oxides of Zn, Mn, Mg and the like may be present.
  • oxide powder is of the generic composition of Formula I:
  • the oxide powder is preferably provided in powder form or suitable for rendering in powder form with a particle size of less than 45 micron.
  • the powder may additionally contain growth components such as magnetite, apatite and the like in particular in crystalline form.
  • the powder may be present in crystalline or amorphous form, depending on the manufacture thereof.
  • the powder may additionally comprise medicaments for controlled release, for example bacteriostatics or antibiotics and the like.
  • the oxide powder may be present with additional stabilising agents or the like to prevent premature reaction during storage.
  • a process for the preparation of a fused oxide powder as hereinbefore defined comprising in a first stage providing oxide precursor(s) in desired amount and subjecting to elevated temperature in the range 900-1500°C, preferably 1300-1500°C for up to 2 l A hours, for example I-2 2 hours, in a second stage fast quenching into cold water to obtain a glass "frit" and in a third stage grinding to provide a powder in desired particle size.
  • a desired particle size may be obtained by sieving through a 150BS mesh, preferably, 350 BS mesh sieve.
  • the oxide melt in the case of a mixed oxide may comprise only those oxides which are known to be stable at elevated temperature whereby a fused mixed oxide powder is provided of only some of the desired components.
  • the oxide powder may then be blended with additional oxide combinations at ambient temperature thereby avoiding cross reaction.
  • composition comprising an oxide powder as hereinbefore defined together with a water soluble polyacid.
  • the water soluble acid may be present in aqueous form or as a powder in which case additional water is added to the composition.
  • the composition comprises 15-85%wt oxide powder, 3-50%wt polyacid and 5- 70%wt water.
  • the composition may comprise additional chelating agents, hardeners such as MgCl 2 , and the like.
  • the respective component amounts of the composition may be selected in known manner for ease of mixing (increased amount of water for example 35 - 70 %wt water, preferably with increased amount of polyacid and reduced amount of oxide powder for example 20 - 50 %wt polyacid, 15 - 55 % wt oxide powder), increased strength (increased amount of oxide powder for example 40 - 85 %wt oxide powder, preferably with reduced amount of polyacid and of water for example 3 - 35 %wt polyacid, 5 - 50 %wt water) and the like within the hereinbefore defined range. Selection of respective amounts may be made with reference to the desired use, setting time and the like.
  • a polyacid as hereinbefore defined is preferably any water soluble poly (carboxy lie acid), for example prepared by the homo-polymerisation and co-polymerisation of olefinically unsaturated aliphatic carboxylic acids, for example acrylic acid, 2-chloroacrylic acid, 3-chloroacrylic acid, 2- bromoacrylic acid, 3-bromoacrylic acid, methacrylic acid, itaconic acid, maleic acid, glutaconic acid, aconitic acid, citraconic acid, mesaconic acid, fumaric acid and tiglic acid.
  • carboxylic acids for example acrylic acid, 2-chloroacrylic acid, 3-chloroacrylic acid, 2- bromoacrylic acid, 3-bromoacrylic acid, methacrylic acid, itaconic acid, maleic acid, glutaconic acid, aconitic acid, citraconic acid, mesaconic acid, fumaric acid and tiglic acid.
  • Suitable monomers for co-polymerising with the unsaturated aliphatic carboxylic acids include olefinically unsaturated aliphatic compounds such as for example acrylamide, acrylonitrile, vinyl chloride, allyl chloride, vinyl acetate and 2-hydroxyethyl methacrylate. Ter and higher polymers may be used if desired. Particularly preferred are the homopolymers and co-polymers of acrylic acid.
  • a polyacid may have a molar weight in the range 10 4 -10 6 and may have a chain length of the order of 75,000.
  • Other polyacids may be employed as known in the art in addition to or in place of the above preferred polyacids, for example as disclosed in WO 97/31877 which discloses the use of poly(vinyl phosphonic acid).
  • the water: polyacid weight ratio may be 0.2 - 0.8 :1, preferably 0.50-0.65:1, more preferably 0.58-0.62:1.
  • the amount of water may be determined in known manner to correspond to the above amounts for aqueous form polyacid.
  • the composition is suited for admixing with an initiator in known manner to promote the setting reaction immediately prior to use.
  • Any known initiator may be employed as known in the art.
  • Initiator may be present in amount of up to 20%wt, preferably 0.01-10%wt for example approximately 5%wt based on the weight of the polyacid.
  • Initiating agents according to the present invention are particularly those containing chelating hydroxy or carboxyl groups or both, such as for example ethylene diamine terra-acetic acid, salicylic acid, citric acid, 2,4 and 2,6-dihydroxybenzoic acids, dihydroxy tartaric acid, nitrilotriacetic acid, tartaric acid, mellitic acids and polyglycols and the like.
  • initiator comprises 5%wt of tartaric or citric acid.
  • a chelating agent may be present in the form of metal chelate, particularly a di-or tri-valent metal chelate such as complexes of beta- diketones with aluminium and chromium for example aluminium and cliromium triacetylacetonates, and ethylene diamine tetraacetic acid complexes of zinc and copper as disclosed in GB 1422337.
  • a two part cement kit comprising in a first component a mixture of an oxide powder as hereinbefore defined and dry polyacid as hereinbefore defined in ratios as hereinbefore defined and in a second component an initiator and water or dilute polyacid in amount as hereinbefore defined.
  • the kit is suited for admixing prior to use to promote the setting reaction.
  • the kit may be provided in any suitable form, for example as known in the art the separate components may be encapsulated and one capsules contents released into the other and subject to vigorous rapid mixing; or two separate vials may be provided for admixing in a suitable vessel; the initiator may be provided in manner for injection into the mixed first component; or any other means of admixing may be appropriate.
  • an oxide powder or a composition as hereinbefore defined in biomedical, dentistry or general industrial application.
  • the oxide powder or composition is suited for biomedical use as replacement for PMMA as a bone cement, for repair of the ossicular chain and fixation of cochlear implants, for maxillofacial or craniofacial surgery, for thermal tumour treatment or as replacement for existing commercial plaster of Paris and fibre-glass splint bandages, for use between bone tissue and medical devices such as cochlear implants and orthopaedic (hip, knee, shoulder) prosthesis.
  • the oxide powder or composition of the invention has the potential to fill spaces with adhesive material that gives good fit in any of these applications, and in particular in drug delivery or bone cancer treatment. Moreover the oxide powder or composition has the potential to form a bone cement for unusual fractures for example spinal or fracture non union. Additionally the cement has an advantage in biomedical applications as a coloured cement making revision surgery easier, the cement is typically black in colour. The presence of Fe should also make the resulting cement radio opaque.
  • the oxide powder or composition of the invention provides a cement which gives no inhibition of bone mineralisation and no aluminium induced encephalopathy of brain tissue that may cause death.
  • the cement provided by the oxide powder or composition of the invention has potential for treatment of tumours using thermal treatment, as a ferromagnetic cement in known manner.
  • the oxide powder or composition of the invention has particular dentistry applications in endodontic (route canal) fillers, to form a flexible fluoride releasing cement and in other conventional dentistry applications.
  • such a cement has a general industrial application for general purpose adhesive or cementation as filler material for plugging holes, building applications and the like, and may be useful for ceramics and metals in particular.
  • the cement is characterised by ion-leaching in known manner and this may be used to advantage in any of the above applications as desired.
  • a two part cement kit comprises in a first component a mixture of dry polyalkenoic acid (PAA) and oxide powder according to the invention of Formula I:
  • a second component comprises a 10% tartaric acid solution.
  • the components are typically provided encapsulated in known manner in two capsules and are admixed, with the tartaric acid in an amount of 0.3 g to promote the setting reaction.
  • the admixture forms a cement which is suitable for injection or application for any of the following uses.
  • Example 2 The formulation obtained using the process of Example 1 is injected directly into bone for reconstruction or as bone fracture repair.
  • the cement gives good space filling and adhesion.
  • Example 2 The formulation obtained using the process of Example 1 is injected between bone tissue and an orthopaedic implant.
  • the cement gives good space filling and adhesion.
  • Example 2 The formulation obtained using the process of Example 1 is characterised by ferromagnetic properties and is injected into bone local to a tumour site. The injected cement is then a target for thermal treatment in highly specific localised manner.
  • the formulation obtained using the process of Example 1 is combined with a medicament for release and injected as a bone cement into a site having a known bone infection.
  • the cement degrades by ion leaching and releases the medicament local to the site of infection.
  • the formulation obtained using the process of Example 1 is used for industrial or household ceramics or metals cementation, gives good physical properties and is non-toxic.
  • a cement formed entirely from Fe 2 0 3 also forms a useful cement with applications as in Examples 2 to 6 above and in particular in hyperthermic treatment of tumours (see Example 4).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Structural Engineering (AREA)
  • General Chemical & Material Sciences (AREA)
  • Composite Materials (AREA)
  • Surgery (AREA)
  • Civil Engineering (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Transplantation (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Materials For Medical Uses (AREA)
  • Dental Preparations (AREA)

Abstract

L'invention concerne une poudre d'oxyde pour un ciment de réaction polyacide comprenant de l'oxyde de fer pouvant être mélangé avec un polyacide pour réaction et durcissement, ainsi qu'une composition comprenant cette poudre d'oxyde et un polyacide hydrosoluble. L'invention concerne également un kit pour ciment en deux parties comprenant la poudre d'oxyde et le polyacide, ainsi que l'utilisation de ce ciment en tant que ciment pour les os, pour la réparation de la chaîne ossiculaire et la fixation d'implants cochléaires, pour la chirurgie maxillo-faciale ou cranio-faciale, pour le traitement thermique de tumeur ou en remplacement du plâtre de Paris commercial existant et d'attelles de fibre de verre, pour une utilisation entre du tissu osseux et des dispositifs médicaux tels qu'implants cochléaires ou prothèses orthopédiques (hanche, genou, épaule).
PCT/GB2002/004359 2001-09-28 2002-09-26 Ciment de reaction polyacide Ceased WO2003028670A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0123297.4A GB0123297D0 (en) 2001-09-28 2001-09-28 Polyacid reaction cement
GB0123297.4 2001-09-28

Publications (1)

Publication Number Publication Date
WO2003028670A1 true WO2003028670A1 (fr) 2003-04-10

Family

ID=9922834

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/004359 Ceased WO2003028670A1 (fr) 2001-09-28 2002-09-26 Ciment de reaction polyacide

Country Status (2)

Country Link
GB (1) GB0123297D0 (fr)
WO (1) WO2003028670A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125452A1 (fr) * 2005-05-23 2006-11-30 Universite De Geneve Nanoparticules superparamagnetiques injectables destinees a un traitement par hyperthermie et a la formation d'un implant
WO2007020613A1 (fr) * 2005-08-12 2007-02-22 University Of Limerick Greffon synthetique comprenant un reseau vitreux
WO2008073190A3 (fr) * 2006-11-03 2009-08-13 Kyphon Sarl Matières et méthodes pour l'administration de traitements médicaux localisés

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422337A (fr) * 1972-04-18 1976-01-28
JPS58188328A (ja) * 1982-04-26 1983-11-02 Ricoh Co Ltd 磁気記録媒体
EP0361797A1 (fr) * 1988-09-26 1990-04-04 Kyoto University Corps céramique thermogène pour l'hyperthermie et sa méthode de production
JPH11178941A (ja) * 1997-12-19 1999-07-06 Nippon Electric Glass Co Ltd 温熱治療用セメント材料及び温熱治療用インプラント材

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422337A (fr) * 1972-04-18 1976-01-28
JPS58188328A (ja) * 1982-04-26 1983-11-02 Ricoh Co Ltd 磁気記録媒体
EP0361797A1 (fr) * 1988-09-26 1990-04-04 Kyoto University Corps céramique thermogène pour l'hyperthermie et sa méthode de production
JPH11178941A (ja) * 1997-12-19 1999-07-06 Nippon Electric Glass Co Ltd 温熱治療用セメント材料及び温熱治療用インプラント材

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 198350, Derwent World Patents Index; Class A85, AN 1983-840954, XP002229512 *
EBISAWA Y ET AL: "Bioactivity of ferrimagnetic glass-ceramics in the system FeO-Fe2O3-CaO-SiO2", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 18, no. 19, 1997, pages 1277 - 1284, XP004088021, ISSN: 0142-9612 *
KAMITAKAHARA, M. ET AL.: "Preparation of a Al-Free Glass-Ionomer Cement", J. CERAM. SOC. JPN., vol. 108, no. 12, December 2000 (2000-12-01), pages 1117 - 1118, XP009004413 *
LARRABEE, R. A. III ET AL.: "Ferric Calcium Phosporous Oxide (FECAP) Ceramic for Rebuiding Bone", BIOMED SCI INSTRUM. BIOMEDICAL SCIENCE INSTRUMENTATION, vol. 29, no. -, 1993, pages 59 - 64, XP009004430 *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 12 29 October 1999 (1999-10-29) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125452A1 (fr) * 2005-05-23 2006-11-30 Universite De Geneve Nanoparticules superparamagnetiques injectables destinees a un traitement par hyperthermie et a la formation d'un implant
WO2007020613A1 (fr) * 2005-08-12 2007-02-22 University Of Limerick Greffon synthetique comprenant un reseau vitreux
US7981972B2 (en) 2005-08-12 2011-07-19 University Of Limerick Synthetic graft having a glass network
WO2008073190A3 (fr) * 2006-11-03 2009-08-13 Kyphon Sarl Matières et méthodes pour l'administration de traitements médicaux localisés

Also Published As

Publication number Publication date
GB0123297D0 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
US5296026A (en) Phosphate glass cement
AU2004263134B2 (en) Method and product for phosphosilicate slurry for use in dentistry and related bone cements
EP2470154B1 (fr) Composition d'agrégat minéral de trioxyde (mta) et utilisation de celle-ci
JP2003518989A (ja) 生体活性な骨粗鬆症用骨セメント
Madfa et al. Endodontic repair filling materials: a review article.
JPS6242625B2 (fr)
Wu et al. Fast-setting and anti-washout tricalcium silicate/disodium hydrogen phosphate composite cement for dental application
US20110009511A1 (en) Glass Polycarboxylate Cements
EP0883586B1 (fr) Ciment obtenu par reaction des polyacides organiques avec une base
ES2365091B1 (es) Un cemento inorgánico para aplicaciones biomédicas, procedimiento para su preparación y uso de dicho cemento.
Ilić et al. Physico-chemical and biological properties of dental calcium silicate cements-literature review
WO2003028670A1 (fr) Ciment de reaction polyacide
Assadian et al. A review of endodontic bioceramics
Zandi Karimi Development of glass ionomer cements with improved mechanical and remineralizing properties by incorporation of 45S5 Bioglass®-ceramic
EP2938316A1 (fr) Nouveau ciment verre ionomère
JPH06172008A (ja) 硬化性組成物
JPH0523389A (ja) 医科用または歯科用硬化性組成物
JPH0763502B2 (ja) 人体硬組織代替組成物
Miglani et al. Bioceramics: Root‐End Filling Material
JPH07194686A (ja) 生体用セメント
JPS6219507A (ja) 歯科用セメント
JPH04329961A (ja) 医科用または歯科用硬化性組成物
JP2742279B2 (ja) 歯科用セメント材料
Kobayashi¹ et al. Mechanical and biological properties of alumina bead composite
Amit Sinha et al. An update on the concepts and application of mineral trioxide aggregate-part I: physicochemical properties and mechanism of action.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP